BRPI0410707A - composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios - Google Patents

composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios

Info

Publication number
BRPI0410707A
BRPI0410707A BRPI0410707-1A BRPI0410707A BRPI0410707A BR PI0410707 A BRPI0410707 A BR PI0410707A BR PI0410707 A BRPI0410707 A BR PI0410707A BR PI0410707 A BRPI0410707 A BR PI0410707A
Authority
BR
Brazil
Prior art keywords
dependent diseases
hormone dependent
treatment
composition
antiestrogens
Prior art date
Application number
BRPI0410707-1A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Jens Hoffmann
Martin Schneider
Gerhard Siemeister
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410707(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0410707A publication Critical patent/BRPI0410707A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO QUE COMPREENDE ANTAGONISTAS DE RECEPTORES DE PROGESTERONA E ANTIESTROGêNIOS PUROS PARA A PROFILAXIA E TRATAMENTO DE DOENçAS DEPENDENTES DE HORMÈNIOS". A presente invenção refere-se a métodos e usos para prevenir ou tratar doenças dependentes de hormónios, particularmente câncer de mama, em um mamífero, por uma combinação de uma antiprogestina, particularmente a antiprogestina 11<225>-(4-acetilfenil)-17b-hidróxi-17a-(1,1,2,2,2-pentafluoretil)-estr a-4,9-dien-3-ona ou um derivado ou análogo farmaceuticamente aceitável da mesma, e um antiestrogênio puro, particularmente um composto da fórmula geral (I), como definido no relatório descritivo, como por exemplo, 11b-flúor-17a-metil-7a-{5-¢metil-(8,8,9,9,9-pentafluomonil)-amino!-pe ntil}-estra-1,3,5(10)-trieno-3,17b-diol. A invenção refere-se ainda a composições farmacêuticas que compreendem a dita combinação.
BRPI0410707-1A 2003-05-28 2004-05-27 composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios BRPI0410707A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
PCT/EP2004/005732 WO2004105768A1 (en) 2003-05-28 2004-05-27 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
BRPI0410707A true BRPI0410707A (pt) 2006-06-13

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410707-1A BRPI0410707A (pt) 2003-05-28 2004-05-27 composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios

Country Status (18)

Country Link
US (3) US20040242551A1 (pt)
EP (2) EP1834644A3 (pt)
JP (1) JP2006528226A (pt)
KR (1) KR20060005412A (pt)
CN (1) CN1893955A (pt)
AR (1) AR044450A1 (pt)
AU (1) AU2004243500A1 (pt)
BR (1) BRPI0410707A (pt)
CA (1) CA2524750A1 (pt)
CL (1) CL2004001317A1 (pt)
EA (1) EA011506B1 (pt)
MX (1) MXPA05012841A (pt)
NO (1) NO20056153L (pt)
PE (1) PE20050207A1 (pt)
TW (1) TW200505936A (pt)
UY (1) UY28334A1 (pt)
WO (1) WO2004105768A1 (pt)
ZA (1) ZA200510449B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
AU2004247551A1 (en) * 2003-06-10 2004-12-23 Fuji Photo Film Co., Ltd. Thiadiazoline derivative
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
JP2010524997A (ja) * 2007-04-23 2010-07-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｂｒｃａ単独での、又は抗エストロゲン薬を伴った組み合わせ物としての使用のためのプロゲステロン受容体拮抗薬
US20160296534A1 (en) * 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
CN117534720A (zh) * 2022-08-01 2024-02-09 香港中文大学（深圳） 环戊烷多氢菲衍生物及其制备方法和应用
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36654A (en) * 1970-04-24 1974-07-31 Ciba Geigy Ag 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
US7378406B2 (en) * 2000-10-18 2008-05-27 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
AU2002223619B2 (en) * 2000-10-18 2006-08-24 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
WO2004105768A8 (en) 2006-04-06
US20070238714A1 (en) 2007-10-11
US20040242551A1 (en) 2004-12-02
EP1628669A1 (en) 2006-03-01
MXPA05012841A (es) 2006-02-13
US20050014736A1 (en) 2005-01-20
CN1893955A (zh) 2007-01-10
JP2006528226A (ja) 2006-12-14
NO20056153L (no) 2006-02-22
EA011506B1 (ru) 2009-04-28
UY28334A1 (es) 2004-12-31
CA2524750A1 (en) 2004-12-09
WO2004105768A1 (en) 2004-12-09
AU2004243500A1 (en) 2004-12-09
EP1834644A2 (en) 2007-09-19
EA200501739A1 (ru) 2006-06-30
EP1834644A3 (en) 2007-11-07
ZA200510449B (en) 2007-04-25
CL2004001317A1 (es) 2005-05-06
KR20060005412A (ko) 2006-01-17
TW200505936A (en) 2005-02-16
PE20050207A1 (es) 2005-04-28
AR044450A1 (es) 2005-09-14

Similar Documents

Publication Publication Date Title
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BRPI0516243C1 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
EA201000157A1 (ru) Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
ZA200709188B (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MXPA05012841A (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
BR112022009942A2 (pt) Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
BRPI0606750A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica
AR066231A1 (es) Combinacion de antagonista del receptor de progesterona con atiestrogenos no esteroidales para usar en enfermedades mediadas por brca (genes supresores de tumores)
BR112022014933A2 (pt) Compostos e composições para uso no tratamento de distúrbios de pele
PE20020520A1 (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.